Table 5.

Univariate and multivariate analyses for OS of ovarian cancer

Variable	n (%)	Median (months)	p value
Age:
<70	118 (94.4 %)	46.0	0.022
≥70	7 (5.6 %)	14.8
Performance status WHO:
▪ 0	19 (15.2 %)	NR	0.28
▪ Other	106 (84.8)	36.2
FIGO stage:
▪ Early (I,II)	24 (19.2 %)	NR	0.003
▪ Advanced (III, IV)	101 (80.8 %)	33.3
Chemotherapy regimen:
▪ With paclitaxel	113 (90.4 %)	46.1	0.035
▪ Without paclitaxel	12 (9.6 %)	16.6
Chemotherapy regimen:
▪ With cisplatin	55 (44.0 %)	50.5	0.24
▪ With carboplatin	70 (56.0 %)	32.3
Type of histology:
▪ Serous	68 (54.4 %)	33.2	0.047
▪ Other	57 (45.6 %)	NR
Grading:
▪ 1 and 2	45 (36.0 %)	49.8	0.53
▪ 3 and unspecified	80 (64.0 %)	35.6
Primary surgery:
▪ Optimal (<1 cm)	77 (61.6 %)	51.8	0.028
▪ Suboptimal (>1 cm)	48 (38.4 %)	30.0
BRCA1 status:
▪ Wild type	108 (86.4 %)	35.6	0.041
▪ Germline mutation	17 (13.6 %)	NR
Multivariate analysis
Variable	HR (95 % CI)		p value
Age:
<70	0.15 (0.053 – 0.417)		< 0.001
≥70
Primary surgery:
▪ Optimal (<1 cm)	0.39 (0.205 – 0.715)		0.003
▪ Suboptimal (>1 cm)
BRCA1 status:
▪ Germline mutation	0.14 (0.032 – 0.650)		0.012
▪ Wild type

NR not reached